Theraclion has appointed Vincent Gardès as Chairman of its Board of Directors, effective immediately, to strengthen its governance during a period of commercial expansion and regulatory progress. The appointment follows the company's recent achievements, including MDR certification, the first clinical implementation in China, and the submission of its Sonovein® file to the FDA. Gardès succeeds Claude Lenoir, who served as Interim Chairman since June 18, 2026, and remains a Director of the company.

The Board of Directors met on July 8, 2026, to finalize the appointment. Gardès has been a Director since the General Meeting of June 18, 2026, after serving as an observer in recent months. His appointment comes as Theraclion gains commercial momentum in Europe and secures a Category III CPT code in the United States. The company also recently completed a successful capital increase.

Strategic Milestones

Theraclion has reached several key milestones that position it for growth:

• MDR Certification: Achieved under EU 2017/745 for Sonovein®.
• FDA Submission: The Sonovein® file has been submitted for review.
• US Market Access: Granted a Category III CPT code.
• Global Expansion: First clinical implementation in China and growing adoption in Europe.

Vincent Gardès is a recognized MedTech executive with 30 years of experience in value creation for innovative medical devices. He previously served as CEO of Vexim, leading the company through its acquisition by Stryker. He also led Germitec's commercial development in Europe and entry into the US market, and currently leads Amber Implants through its commercialization phase.

Leadership Commentary

Vincent Gardès expressed his commitment to accelerating Theraclion's commercial strategy. "I am honoured by the trust placed in me by the Directors of Theraclion. The company has a unique technology, solid clinical results and remarkable momentum across all of its markets: in Europe, where Sonovein® is already adopted in clinical practice, and in the United States, where the fundamentals of market access are falling into place," he stated.

Martin Deterre, Chief Executive Officer of Theraclion, highlighted the strategic value of the appointment. "The appointment of Vincent Gardès is excellent news for Theraclion. His track record in the international development of innovative MedTech companies is exactly what Theraclion needs today. We have been working together for several months; this collaboration is already remarkably smooth and we fully share the same strategic vision," Deterre said.

About Theraclion

Theraclion is a French MedTech company developing Sonovein®, a robotic platform using High-Intensity Focused Ultrasound (HIFU) for non-invasive varicose vein therapy. The technology requires no incisions or operating room, leaves no scars, and allows patients to resume daily activities immediately. Sonovein® has been adopted by more than a dozen centres worldwide and used in over 4,000 procedures. The company is based in Malakoff, Paris, and employs approximately 40 people.

Theraclion has disclosed the total number of voting rights and shares comprising its share capital as of June 30, 2026. The filing provides details on the theoretical and actual voting rights attached to the company's shares.

Share Capital and Voting Rights

The company reported a total of 73,123,311 shares. The total number of theoretical voting rights stood at 89,137,355, while the total number of real voting rights was 87,570,061.

Regulatory Definitions

Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares stripped of voting rights, in accordance with Article 223-11 of the AMF's General Regulation. Actual voting rights correspond to the total number of voting rights exercisable at the Annual General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares stripped of voting rights.

About Theraclion

Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound. High-Intensity Focused Ultrasound (HIFU) requires no incisions or operating room, leaves no scars and allows patients to immediately resume their daily activities. The HIFU method concentrates therapeutic ultrasound toward an internal focal point from outside the body.

Theraclion is developing Sonovein®, a HIFU robotic platform for the treatment of varicose veins, CE-marked under MDR (EU 2017/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein® has been adopted by more than a dozen centres worldwide and has been used in more than 4,000 procedures. In the United States, Sonovein® is not yet available for sale. Based in Malakoff (Paris), the Theraclion team consists of approximately 35 people.